The idea of personalised cancer therapy has already been demonstrated by the use of epidermal growth factor receptor inhibitors in lung cancer, where only ∼10% of patients harbour epidermal growth factor mutations and most fit a particular profile (adenocarcinoma, never-smoker, East-Asian ethnic origin and female). This evidence concerns the gene EGFR and lung cancer.